Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?

AbbVie’s first-half 2026 oncology revenue fell 2.8% year over year to $3.28 billion as Imbruvica sales dropped 27.1% to $1.09 billion amid competition and IRA-related pricing changes. Growth in Venclexta (+9.6% to $1.54 billion), Elahere (+19.3% to $409 million) and Epkinly (+52.2% to $186 million), plus the May approval of Decnupaz, partially offset the decline. AbbVie is expanding its oncology pipeline through ADCs, T-cell engagers and bispecifics, but 2026 and 2027 EPS estimates have fallen over the past 60 days.

Analysis

The investable issue is not whether AbbVie can assemble oncology assets, but whether it can replace high-margin mature cash flows before the market discounts another patent-expiry cycle. The new portfolio is fragmented across small indications and partnership-heavy programs, implying higher launch spend, royalty leakage and slower operating leverage than a single blockbuster. Near-term earnings sensitivity therefore remains skewed to execution in immunology and the pace of legacy-drug erosion, rather than pipeline optionality that is unlikely to be capitalized fully for 12-24 months.

AbbVie’s apparent valuation discount is not automatically a catalyst while consensus EPS is falling: the market may be assigning a lower multiple to uncertainty around the durability and economics of replacement revenues. A better oncology operating read-through may accrue to ADC-platform leaders and manufacturing suppliers, including Daiichi Sankyo (4568 JP) and Lonza (LONN SW), because diversified clinical activity expands outsourced biologics/ADC capacity demand regardless of which individual program wins. Conversely, AstraZeneca’s much larger oncology mix provides greater upside to successful launches but materially higher exposure to trial misses, reimbursement pressure and competitive displacement.

Contrarian view: oncology diversification could be incrementally positive for AbbVie’s terminal multiple because it reduces single-asset concentration, but the article offers no proof of commercial differentiation, pivotal efficacy, safety, or deal economics. Until management demonstrates that newer products can generate enough incremental gross profit to offset erosion and launch investment, this is a monitoring catalyst rather than a reason to underwrite an earnings upgrade. The key 1-3 month test is whether next-quarter guidance and 2027 consensus stabilize; a further cut would signal that the replacement narrative is not yet translating into cash earnings.

Key Decisions for Investors

• Remain neutral ABBV over the next 1-3 months; do not buy the headline-driven oncology narrative. Upgrade only if management holds or raises full-year guidance and 2027 consensus EPS revisions turn positive; a further guidance cut is the thesis falsifier.
• Express relative quality through long AZN / short ABBV in equal dollar amounts for 3-6 months if oncology-growth momentum remains the factor. AZN has more direct operating leverage to oncology execution, while ABBV retains a legacy-erosion overhang; exit if AZN reports a material pivotal-trial failure or ABBV delivers an oncology-led guidance increase.
• Avoid short MRK solely on oncology concentration: Keytruda concentration creates longer-dated loss-of-exclusivity risk, but near-term cash generation can support the multiple. Set a watch item around confirmed post-LOE volume/pricing assumptions and competitor data rather than initiating before those estimates are disclosed.
• Monitor ADC manufacturing capacity and pricing as a second-order signal; consider LONN SW only after confirming order-book growth and utilization, since broad ADC pipeline activity does not guarantee commercial-scale demand. A deterioration in biotech funding or clinical discontinuations would invalidate the capacity-tightness thesis.